GSK Leads Target-Validation Collaboration With EBI And Wellcome Trust
This article was originally published in The Pink Sheet Daily
Executive Summary
Following its February participation in the NIH-led Accelerating Medicines Partnership, GSK now is joining with the European Bioinformatics Institute and Wellcome Trust Sanger Institute on a broad-based target-validation effort headquartered in the U.K. The collaboration’s work will be non-competitive and available to all.
You may also be interested in...
NIH And 10 Biopharmas Hatch Plan To Accelerate And Improve Therapeutic Pathway Research
With $230 million from industry and NIH, the Accelerating Medicines Partnership will seek to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.